MenQuadfi

Meningococcal group A, C, W & Y conjugate vaccine

Active immunisation of individuals ≥12 mth against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, & Y.

IM Primary vaccination Individual ≥12 mth 0.5 mL single dose. Booster vaccination 0.5 mL single dose may be used to boost subjects who have previously received a meningococcal vaccine containing the same serogroups.

Hypersensitivity to MenQuadfi or after previous administration of MenQuadfi or a vaccine containing the same components.

Should not be administered SC, intravascularly or intradermally. Appropriate medical treatment & supervision should always be readily available in case of an anaphylactic event following vaccine administration. Postpone vaccination in individuals suffering from an acute severe febrile illness. Risk of syncope & other anxiety-related reactions as a psychogenic response to needle inj. Caution in individuals w/ thrombocytopenia or any coagulation disorder. Will only protect against Neisseria meningitidis groups A, C, W, & Y. Will not protect against any other Neisseria meningitidis groups. Consider administering a booster dose if an individual is expected to be at particular risk of exposure to serogroup A & received a MenQuadfi dose approx >1 yr previously. Consider risk of MenA infection in high-risk individuals who received serogroup C meningococcal conjugate vaccine in the 1st yr of life. Adequate immune response may not be elicited in patients receiving immunosuppressive treatment or patients w/ immunodeficiency. Increased risk of invasive disease caused by Neisseria meningitidis groups A, C, W, & Y in patients w/ familial complement deficiencies (eg, C5 or C3 deficiencies) & those receiving treatments that inhibit terminal complement activation (eg, eculizumab), even if they develop Abs following MenQuadfi vaccination. No data available on immunocompromised patients. Not a substitute for routine tetanus immunisation. Should only be used during pregnancy & breast-feeding if expected benefits outweigh potential risks. Safety & immunogenicity in individuals <12 mth have not yet been established.

Fever, inj site swelling/erythema. Individuals ≥2 yr: Headache; myalgia; malaise. Individuals 12-23 mth: Appetite lost; irritability; drowsiness; abnormal crying, inj site tenderness/pain; vomiting, diarrhoea.

Adequate immune response may not be elicited in patients receiving immunosuppressives. Consider separate administration of MenQuadfi & 13-valent pneumococcal polysaccharide conjugated vaccine in childn 12-23 mth at high risk for serogroup A disease. Concomitant vaccines should always be administered at separate inj sites & preferably contralateral.

Vaccines, Antisera & Immunologicals

J07AH - Meningococcal vaccines ; Used for active immunizations.

P₁S₁S₃